At SIU Medicine, our researchers perform clinical trials and research studies with the aim of translating findings into new, more effective treatments.
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).
The primary goals of this study are to determine whether treatment of obstructive sleep apnea with positive airway pressure starting shortly after accute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event and (2) improves stroke outcomes at 3 months in patients who experienced ischemic stroke.
